NextBiomed nearing 80% enrollment in FDA Nexsphere-F trial
NextBiomedical said its FDA trial for Nexsphere-F is about 80% enrolled and progressing as planned, and it is seeking a strategic U.S. partner to support market entry.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.